PT1838315E - 4-feniltetra-hidro-isoquinolinas substituídas, processo para a sua preparação, a sua utilização como medicamento, bem como medicamento que as contém - Google Patents

4-feniltetra-hidro-isoquinolinas substituídas, processo para a sua preparação, a sua utilização como medicamento, bem como medicamento que as contém Download PDF

Info

Publication number
PT1838315E
PT1838315E PT58235730T PT05823573T PT1838315E PT 1838315 E PT1838315 E PT 1838315E PT 58235730 T PT58235730 T PT 58235730T PT 05823573 T PT05823573 T PT 05823573T PT 1838315 E PT1838315 E PT 1838315E
Authority
PT
Portugal
Prior art keywords
drug
phenyltetrahydroisoquinolines
substituted
producing
methods
Prior art date
Application number
PT58235730T
Other languages
English (en)
Inventor
Lang Dr Hans-Jochen
Klaus Wirth
Armin Hofmeister
Uwe Heinelt
Thomas Licher
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT1838315E publication Critical patent/PT1838315E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT58235730T 2005-01-12 2005-12-30 4-feniltetra-hidro-isoquinolinas substituídas, processo para a sua preparação, a sua utilização como medicamento, bem como medicamento que as contém PT1838315E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005001411A DE102005001411A1 (de) 2005-01-12 2005-01-12 Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
PT1838315E true PT1838315E (pt) 2014-05-26

Family

ID=36121409

Family Applications (1)

Application Number Title Priority Date Filing Date
PT58235730T PT1838315E (pt) 2005-01-12 2005-12-30 4-feniltetra-hidro-isoquinolinas substituídas, processo para a sua preparação, a sua utilização como medicamento, bem como medicamento que as contém

Country Status (31)

Country Link
US (1) US7868003B2 (pt)
EP (1) EP1838315B1 (pt)
JP (1) JP2008526906A (pt)
KR (1) KR20070094916A (pt)
CN (1) CN101184488A (pt)
AR (1) AR053326A1 (pt)
AU (1) AU2005324833A1 (pt)
BR (1) BRPI0519854A2 (pt)
CA (1) CA2594419A1 (pt)
CR (1) CR9191A (pt)
DE (1) DE102005001411A1 (pt)
DK (1) DK1838315T3 (pt)
DO (1) DOP2006000011A (pt)
ES (1) ES2470980T3 (pt)
GT (1) GT200600017A (pt)
IL (1) IL184314A0 (pt)
MA (1) MA29227B1 (pt)
MX (1) MX2007008269A (pt)
MY (1) MY142493A (pt)
NI (1) NI200700162A (pt)
NO (1) NO20074084L (pt)
NZ (1) NZ556080A (pt)
PA (1) PA8659501A1 (pt)
PT (1) PT1838315E (pt)
RU (1) RU2398766C2 (pt)
TN (1) TNSN07263A1 (pt)
TW (1) TW200637842A (pt)
UA (1) UA88941C2 (pt)
UY (1) UY29333A1 (pt)
WO (1) WO2006074813A1 (pt)
ZA (1) ZA200704728B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110050718A (ko) * 2008-09-02 2011-05-16 사노피-아벤티스 치환된 아미노인단 및 그의 유사체, 및 그의 제약 용도
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
BR112012015868A2 (pt) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
WO2012151559A2 (en) * 2011-05-05 2012-11-08 Rose Pharmaceuticals, Llc Cytotoxic therapy by proton flux modulation
KR20230132619A (ko) 2013-04-12 2023-09-15 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
SG11201700398RA (en) * 2014-07-25 2017-02-27 Taisho Pharmaceutical Co Ltd Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
AU2018205400B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EP3565811A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
CN100436420C (zh) 1999-11-03 2008-11-26 Amr科技公司 4-苯基取代的四氢异喹啉及其用于制备药物的用途
DE19960204A1 (de) 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
PT1453810E (pt) * 2001-12-05 2009-05-27 Sanofi Aventis Deutschland 4-feniltetra-hidroisoquinolinas substituídas, processo para a sua preparação, sua utilização como medicamento, bem como medicamento contendo as mesmas
DE10163914A1 (de) 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
GT200600017A (es) 2006-08-28
RU2007130706A (ru) 2009-02-20
TNSN07263A1 (en) 2008-12-31
JP2008526906A (ja) 2008-07-24
ZA200704728B (en) 2008-07-30
EP1838315B1 (de) 2014-03-12
MY142493A (en) 2010-11-30
MX2007008269A (es) 2008-01-16
BRPI0519854A2 (pt) 2009-03-24
WO2006074813A1 (de) 2006-07-20
DK1838315T3 (da) 2014-06-16
NO20074084L (no) 2007-09-28
DOP2006000011A (es) 2006-07-15
NI200700162A (es) 2008-04-21
CR9191A (es) 2007-10-04
KR20070094916A (ko) 2007-09-27
TW200637842A (en) 2006-11-01
AU2005324833A1 (en) 2006-07-20
US20080058328A1 (en) 2008-03-06
PA8659501A1 (es) 2006-09-08
RU2398766C2 (ru) 2010-09-10
US7868003B2 (en) 2011-01-11
CN101184488A (zh) 2008-05-21
IL184314A0 (en) 2007-10-31
NZ556080A (en) 2009-08-28
UA88941C2 (ru) 2009-12-10
AR053326A1 (es) 2007-05-02
EP1838315A1 (de) 2007-10-03
ES2470980T3 (es) 2014-06-24
DE102005001411A1 (de) 2006-07-27
CA2594419A1 (en) 2006-07-20
MA29227B1 (fr) 2008-02-01
UY29333A1 (es) 2006-08-31

Similar Documents

Publication Publication Date Title
IL189914A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
IL186523A0 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
IL184175A (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
IL180874A0 (en) Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
PL1928882T3 (pl) (S)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowania farmaceutyczne
IL185804A0 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
IL191655A0 (en) Novel compounds, their preparation and use
IL179170A0 (en) Novel substituted thiophenecarboxamides, their production and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL178887A0 (en) Novel beta agonists, method for producing the same and their use as drugs
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
ZA200803116B (en) Novel indole-containing beta agonists, method for producing them and their use as drugs
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
PL1999112T3 (pl) Podstawione 2-amino-4-fenylo-dihydrochinoliny, sposób ich wytwarzania, ich zastosowanie jako leku i lek je zawierający
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
ZA200608023B (en) Novel substituted thiophenecarboxamides, their production and their use as medicaments
ZA200805284B (en) Tetrafluorotoluene compound, method for producing same and use thereof
IL183438A0 (en) Substituted indoles, compositions containing them, method for the production thereof and their use